StreetInsider.com News Articles

Form DEFA14A Entera Bio Ltd.

Wed, 03 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260603/26598993.html

Form DEFA14A Entera Bio Ltd.

Wed, 03 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260603/26598993.html

Form ARS Entera Bio Ltd. For: Jun 03

Wed, 03 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260603/26598942.html

Form ARS Entera Bio Ltd. For: Jun 03

Wed, 03 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260603/26598942.html

Form DEF 14A Entera Bio Ltd. For: Jun 03

Wed, 03 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260603/26598807.html

Form DEF 14A Entera Bio Ltd. For: Jun 03

Wed, 03 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260603/26598807.html

Entera Bio's EB613 data selected for presentation at ENDO 2026

Thu, 28 May 2026 08:50:34 -0400

Entera Bio Ltd. (NASDAQ: ENTX) announced that clinical data for its EB613 oral osteoporosis treatment has been selected for a late-breaking oral presentation at the ENDO 2026 annual meeting of the Endocrine Society, scheduled for June 13-16 in Chicago.

The presentation will focus on new clinical data supporting a single EB613 tablet formulation as the company's candidate for a planned Phase 3 study in postmenopausal women with osteoporosis. The session is scheduled for June 14 at 3:30-4:15 PM CT.

EB613 is an oral form of PTH(1-34), a parathyroid hormone fragment used for bone building treatment. The company previously completed a Phase 2

Entera Bio's EB613 data selected for presentation at ENDO 2026

Thu, 28 May 2026 08:50:34 -0400

EB613 is an oral form of PTH(1-34), a parathyroid hormone fragment used for bone building treatment. The company previously completed a Phase 2

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipelin

Thu, 28 May 2026 08:50:00 -0400

TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts across its oral peptide pipeline have been accepted for presentation at ENDO 2026, the annual meeting of the Endocrine Society, taking place June 13-16, 2026 in Chicago, Illinois, USA. Notably, new clinical data supporting Entera’s single EB613 tablet as the final candidate for its planned Phase 3 study in postmenopausal women with osteoporosis was selected for a Late Breaking Oral Presentation.

Abstract Title: Transforming Anabolic Treatments

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipelin

Thu, 28 May 2026 08:50:00 -0400

TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts across its oral peptide pipeline have been accepted for presentation at ENDO 2026, the annual meeting of the Endocrine Society, taking place June 13-16, 2026 in Chicago, Illinois, USA. Notably, new clinical data supporting Entera’s single EB613 tablet as the final candidate for its planned Phase 3 study in postmenopausal women with osteoporosis was selected for a Late Breaking Oral Presentation.

Abstract Title: Transforming Anabolic Treatments

Form EFFECT Entera Bio Ltd.

Mon, 18 May 2026 06:04:00 -0400
si-local-file:///var/storage/secattach/20260518/26509689.html

Form EFFECT Entera Bio Ltd.

Mon, 18 May 2026 06:04:00 -0400
si-local-file:///var/storage/secattach/20260518/26509689.html

Form 424B3 Entera Bio Ltd.

Fri, 15 May 2026 16:12:00 -0400
si-local-file:///var/storage/secattach/20260515/26505283.html

Form 424B3 Entera Bio Ltd.

Fri, 15 May 2026 16:12:00 -0400
si-local-file:///var/storage/secattach/20260515/26505283.html

Form PRE 14A Entera Bio Ltd. For: May 14

Thu, 14 May 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260514/26494877.html

Form PRE 14A Entera Bio Ltd. For: May 14

Thu, 14 May 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260514/26494877.html

Entera Bio Ltd. (ENTX) Tops Q1 EPS by 4c

Mon, 11 May 2026 06:27:12 -0400

Entera Bio Ltd. (NASDAQ: ENTX) reported Q1 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11).
For earnings history and earnings-related data on Entera Bio Ltd. (ENTX) click here.

Form 4 Entera Bio Ltd. For: May 07 Filed by: Galitzer Hillel

Fri, 08 May 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260508/26461590.html

Form 4 Entera Bio Ltd. For: May 07 Filed by: Galitzer Hillel

Fri, 08 May 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260508/26461590.html

Form 4 Entera Bio Ltd. For: May 07 Filed by: Yaacov-Garbeli Dana

Fri, 08 May 2026 16:28:00 -0400
si-local-file:///var/storage/secattach/20260508/26461573.html

Form 4 Entera Bio Ltd. For: May 07 Filed by: Yaacov-Garbeli Dana

Fri, 08 May 2026 16:28:00 -0400
si-local-file:///var/storage/secattach/20260508/26461573.html

Form 4 Entera Bio Ltd. For: May 07 Filed by: Burshtein Gregory

Fri, 08 May 2026 16:27:00 -0400
si-local-file:///var/storage/secattach/20260508/26461563.html

Form 4 Entera Bio Ltd. For: May 07 Filed by: Burshtein Gregory

Fri, 08 May 2026 16:27:00 -0400
si-local-file:///var/storage/secattach/20260508/26461563.html

Entera Bio Ltd. (ENTX) files for 19.6M share offering by selling stockholders

Fri, 08 May 2026 16:23:32 -0400

Entera Bio Ltd. (NASDAQ: ENTX) has filed for up to 19,569,472 share offering by selling stockholders.

Entera Bio Ltd. (ENTX) files for 19.6M share offering by selling stockholders

Fri, 08 May 2026 16:23:32 -0400

Entera Bio Ltd. (NASDAQ: ENTX) has filed for up to 19,569,472 share offering by selling stockholders.